Xiaojun Hu

Xiaojun Hu

Auto-generated profile, based on publicly available information

Xiaojun Hu

National Institute for Drug Clinical Trial, Beijing Tongren Hospital, Capital Medical University, Beijing, China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 October 2025 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
YDYuyang Dai
Yuyang Dai
FWFeng Wu
Feng Wu
HPHongyan Pang
Hongyan Pang
SNSiyang Ni
Siyang Ni
XHXiaojun Hu
Xiaojun Hu
LLLaiChun Lu
LaiChun Lu
HT006.2.2 is a kind of recombinant human nerve growth factor (rhNGF) eye drop with the potential to treat neurotrophic keratitis. To evaluate the safety, immunogenicity, and pharmacokinetic (PK) characteristics of HT006.2.2 eye drops in Chinese healthy volunteers. This study was divided into three parts. In Part A (single-dose) and Part B (multi-dose), four dose groups were per-specified: 5 µg/mL, 20 µg/mL, 60 µg/mL and 120 µg/mL. Each dose group comprised eight subjects randomized in a 3:1 ratio to receive the HT006.2.2 or placebo. Serum samples were collected for systemic PK analysis and anti-drug antibody (ADA) detection. The Part C comprised two single-dose groups (20 µg/mL and 60 µg/mL), and tear samples were collected at preset time points for tear fluid PK analysis. The drug mass per gram of tears (unit: µg/g) was calculated and used as the drug concentration to recalculate the PK parameters. Safety was evaluated via vital signs monitoring, 12-lead electrocardiogram, clinical laboratory tests, and ophthalmologic assessments (ocular symptoms and signs, slit-lamp microscopy, corneal fluorescein sodium staining, intraocular pressure measurement, and best-corrected visual acuity). Adverse events were collected following the initial administration of the investigational drug and were defined as treatment-emergent adverse events (TEAEs). This study enrolled a total of 163 subjects, with 161 receiving the medication and completing the study as planned. HT006.2.2 showed favorable tolerance across both single-dose and multiple-dose parts. At the highest dose of 120 µg/mL, no maximum tolerated dose (MTD) was reached. No discernible dose-response relationship was identified in the incidence of TEAEs across dosage groups, with the total TEAE rate in HT006.2.2 groups remaining non-exceeding that of the placebo group. Ocular TEAEs included corneal vital dye staining, eye itching, eye pain, conjunctival hyperemia, and decreased visual acuity. In addition, no HT006.2.2 or ADA was detected in the peripheral blood of healthy subjects. Tear fluid PK analysis of HT006.2.2 (20 µg/mL) showed time to peak concentration (Tmax) of 0.17 h, mean peak concentration (Cmax) of 3.63 ± 2.06 µg/g, elimination half-life (t1/2) of 4.21 h. HT006.2.2 eye drops exhibited favorable safety in Chinese healthy subjects, with localized ocular distribution, no systemic exposure, and no detectable ADAs. These findings support the continuation of clinical development for HT006.2.2 in China.

2 July 2025 in Clinical and Translational Science
Verified
Journal Article
Open access
YDYuyang Dai
Yuyang Dai
FWFeng Wu
Feng Wu
SNSiyang Ni
Siyang Ni
XHXiaojun Hu
Xiaojun Hu
YHYing Han
Ying Han
LLLaiChun Lu
LaiChun Lu
HSK39297 is a novel complement factor B inhibitor, and this phase 1 trial was designed to assess its pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability in healthy Chinese subjects. This study included 46 subjects in the single ascending dose (SAD) part (50–600 mg) and 50 subjects in the multiple ascending dose (MAD) part (50–125 mg BID and 200–300 mg QD). Among them, a food effect study was conducted in the SAD 200 mg group. Adverse events (AEs) reported after the initial dose of the study drug were considered treatment‐emergent AEs (TEAEs). Blood samples were collected to measure plasma concentrations of HSK39297 at predefined time points and analyzed at a centralized laboratory. In addition, PD analysis was conducted by measuring complement alternative pathway (AP) activity and Bb concentrations. According to the results, we found single and multiple doses of HSK39297 were safe and well tolerated in all subjects. Within SAD of 50–600 mg dose range, the C max , AUC 0‐ t , and AUC 0‐∞ exhibited nonlinear PK characteristics. The high‐fat meals did not significantly affect the absorption rate and systemic exposure levels of HSK39297, and GMRs for fed versus fasting states were 108.05% (99.66%, 117.15%), 98.73% (89.34%, 109.09%), and 97.86% (84.66%, 113.11%), respectively. In MAD part, dose‐drug exposure showed a linear relationship. PD analysis indicated that oral administration of HSK39297 tablets resulted in dose‐dependent inhibition of the AP activity and Bb concentration. These findings support advancing HSK39297 into later‐phase trials for complement‐mediated glomerular diseases.